5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT)

5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT)

MPJE Core Concept: Medication Therapy Management (MTM) is a distinct service model formalized under Medicare Part D to optimize therapeutic outcomes. Point-of-Care Testing (POCT) in community pharmacy operates under federal Clinical Laboratory Improvement Amendments (CLIA) Certificates of Waiver. Under state test-and-treat protocols, CLIA-waived diagnostic testing enables pharmacists to evaluate infectious or metabolic conditions and immediately initiate protocol-guided prescription drug therapy.

1. Medicare Part D Statutory MTM Framework

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) established mandatory MTM services for targeted Medicare Part D beneficiaries.

MTM Beneficiary Eligibility Criteria

Part D sponsors must enroll targeted beneficiaries who meet three statutory thresholds:

1. Multiple Chronic Diseases: Typically 2 or 3 chronic conditions (e.g., Diabetes, Heart Failure, Hypertension, Dyslipidemia, Asthma/COPD).
2. Multiple Covered Part D Medications: Taking multiple maintenance drugs (typically between 2 and 8 covered Part D drugs).
3. High Annual Drug Spend: Incurring annual covered Part D drug costs that exceed a federally established annual cost threshold (e.g., $5,330 in recent plan years).

Core Service Components of MTM

---

2. Point-of-Care Testing (POCT) & CLIA Waiver Framework

Point-of-Care Testing allows rapid diagnostic evaluation in non-traditional laboratory settings, including community pharmacies.

Clinical Laboratory Improvement Amendments (CLIA)

Federal CLIA regulations classify laboratory testing into three categories based on complexity: High Complexity, Moderate Complexity, and Waived.

• CLIA Certificate of Waiver: Pharmacies performing POCT must obtain a Certificate of Waiver from CMS by submitting Form CMS-116 and paying biennial registration fees.
• Waived Test Definition: Tests cleared by the FDA for home use or simple, un-monitored tests that have an insignificant risk of an erroneous result.
• Strict Compliance Rule: To maintain CLIA-waived status, the pharmacy must follow manufacturer instructions exactly without modification. Any modification of test procedures elevates the test to High Complexity, subjecting the pharmacy to stringent federal lab regulations.

---

3. Authorized CLIA-Waived Tests & Protocol Prescribing Actions

---

4. Test-and-Treat Protocols & Red-Flag Referrals

State legislatures increasingly enact "Test-and-Treat" statutes permitting pharmacists to perform CLIA-waived POCT and immediately prescribe target anti-infective medications.

Protocol Prescribing Workflow

1. Patient Screening: Evaluate symptom duration (e.g., flu symptoms < 48 hours, COVID symptoms < 5 days).
2. Execute Waived Test: Perform CLIA-waived rapid antigen or molecular test following strict manufacturer protocol.
3. Interpret Result & Prescribe: If positive, initiate protocol-specified prescription therapy; if negative, provide supportive care guidance.
4. Mandatory Physician Referral (Red Flags): Pharmacists must immediately refer patients to an urgent care or emergency department if red-flag symptoms are present:
   • High fever (>103°F / 39.4°C) unresponsive to antipyretics
   • Severe respiratory distress, shortness of breath, or oxygen saturation < 92%
   • Immunocompromised state (e.g., active chemotherapy, advanced HIV, organ transplant)
   • Symptoms suggesting severe invasive illness or sepsis

---

5. Quality Control, Safety, and OSHA Compliance

CLIA Quality Control (QC) Practices

• Good Laboratory Practices (GLP): Pharmacies must maintain a dedicated testing area, verify expiration dates of test kits and reagents, and perform routine instrument calibration.
• External Quality Control Testing: Run positive and negative controls provided in test kits with each new lot number, each new shipment, and whenever storage temperatures deviate from manufacturer specifications. All QC results must be logged.

OSHA Bloodborne Pathogens Standard Compliance

Pharmacies conducting capillary blood testing (glucose, lipid, INR, HIV) must strictly comply with OSHA regulations:

• Written Exposure Control Plan: Maintained and updated annually.
• Universal / Standard Precautions: Treating all human blood and body fluids as infectious.
• Engineering & Work Practice Controls: Mandatory use of single-use, auto-disabling safety lancets and immediate disposal into rigid, puncture-resistant Sharps Containers.
• Hepatitis B Vaccination: Must be offered free of charge to all employees with occupational exposure risk within 10 working days of initial assignment.